You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Details for Patent: 9,790,183


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,790,183 protect, and when does it expire?

Patent 9,790,183 protects ERIVEDGE and is included in one NDA.

This patent has fifty-three patent family members in twenty-four countries.

Summary for Patent: 9,790,183
Title:Pyridyl inhibitors of hedgehog signalling
Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: ##STR00001## wherein A, X, Y R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n are as described herein.
Inventor(s): Gunzner-Toste; Janet L. (Piedmont, CA), Sutherlin; Daniel (Burlingame, CA), Stanley; Mark S. (Pacifica, CA), Bao; Liang (Freemont, CA), Castanedo; Georgette M. (Redwood City, CA), Lalonde; Rebecca L. (Portland, OR), Wang; Shumei (Foster City, CA), Reynolds; Mark E. (Millbrae, CA), Savage; Scott J. (Burlingame, CA), Malesky; Kimberly (Boston, MA), Dina; Michael S. (Daly City, CA), Koehler; Michael F. T. (Palo Alto, CA)
Assignee: GENENTECH, INC. (Lexington, MA)
Application Number:15/015,586
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,790,183

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,790,183

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1789390 ⤷  Sign Up C300614 Netherlands ⤷  Sign Up
European Patent Office 1789390 ⤷  Sign Up 122013000074 Germany ⤷  Sign Up
European Patent Office 1789390 ⤷  Sign Up 92278 Luxembourg ⤷  Sign Up
European Patent Office 1789390 ⤷  Sign Up PA2013024 Lithuania ⤷  Sign Up
European Patent Office 1789390 ⤷  Sign Up CA 2013 00050 Denmark ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.